ATE517607T1 - Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung - Google Patents

Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung

Info

Publication number
ATE517607T1
ATE517607T1 AT01998328T AT01998328T ATE517607T1 AT E517607 T1 ATE517607 T1 AT E517607T1 AT 01998328 T AT01998328 T AT 01998328T AT 01998328 T AT01998328 T AT 01998328T AT E517607 T1 ATE517607 T1 AT E517607T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
particles
producing particles
relates
composite active
Prior art date
Application number
AT01998328T
Other languages
English (en)
Inventor
John Staniforth
Matthew Green
David Morton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31891809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517607(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0029261A external-priority patent/GB0029261D0/en
Priority claimed from GB0030946A external-priority patent/GB0030946D0/en
Priority claimed from PCT/GB2001/001606 external-priority patent/WO2001076575A2/en
Priority claimed from GB0124010A external-priority patent/GB0124010D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Priority claimed from PCT/GB2001/005315 external-priority patent/WO2002043701A2/en
Application granted granted Critical
Publication of ATE517607T1 publication Critical patent/ATE517607T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01998328T 2000-11-30 2001-11-30 Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung ATE517607T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0029261A GB0029261D0 (en) 2000-11-30 2000-11-30 Method of making particles for use in a pharmaceutical composition
GB0030946A GB0030946D0 (en) 2000-12-19 2000-12-19 Method of making particles for use in a pharmaceutical composition
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases
GB0124010A GB0124010D0 (en) 2001-10-05 2001-10-05 Pharmaceutical compositions for inhalation
PCT/GB2001/005315 WO2002043701A2 (en) 2000-11-30 2001-11-30 Method of making particles for use in a pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE517607T1 true ATE517607T1 (de) 2011-08-15

Family

ID=31891809

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01998328T ATE517607T1 (de) 2000-11-30 2001-11-30 Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung
AT01998329T ATE382335T1 (de) 2000-11-30 2001-11-30 Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01998329T ATE382335T1 (de) 2000-11-30 2001-11-30 Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation

Country Status (8)

Country Link
US (11) US7736670B2 (de)
EP (6) EP2298279B1 (de)
JP (1) JP5192447B2 (de)
AT (2) ATE517607T1 (de)
CY (2) CY1112338T1 (de)
DK (3) DK1337240T4 (de)
ES (3) ES2474199T3 (de)
PT (4) PT2283818T (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
KR100949539B1 (ko) * 2000-06-27 2010-03-25 벡투라 리미티드 약학 조성물용 입자의 제조 방법
PT1337239E (pt) * 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
PT2283818T (pt) 2000-11-30 2017-10-09 Vectura Ltd Método de preparação de partículas para utilização numa composição farmacêutica
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20050056958A1 (en) * 2003-09-16 2005-03-17 Eastman Kodak Company Forming homogeneous mixtures of organic materials for physical vapor deposition using dry mixing
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0418791D0 (en) * 2004-08-23 2004-09-22 Glaxo Group Ltd Novel process
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
US7951419B2 (en) * 2005-07-21 2011-05-31 Multisorb Technologies, Inc. Dry-coated oxygen-scavenging particles and methods of making them
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US7883039B2 (en) * 2007-02-27 2011-02-08 Collette Nv Continuous granulating and drying apparatus including measurement units
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
JP2011506400A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
WO2010014846A1 (en) * 2008-07-30 2010-02-04 T & T Enterprises Inc. Antioxidant additive
LT3578169T (lt) 2009-02-26 2024-08-26 Glaxo Group Limited Farmaciniai preparatai, apimantys 4-{(1r)-2-[(6-{2-[(2,6-dichlorbenzil) oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenolį
AU2010229668C1 (en) 2009-03-26 2016-09-15 Pulmatrix Operating Co., Inc. Dry powder formulations and methods for treating pulmonary diseases
SG175315A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd A novel formulation of indomethacin
EA201171279A1 (ru) 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Производство инкапсулированных наночастиц с высокой объемной долей
CN102740835A (zh) * 2009-04-24 2012-10-17 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备
EP3111926B1 (de) 2009-05-29 2019-12-11 Pearl Therapeutics, Inc. Zusammensetzungen, verfahren und systeme für die respiratorische verabreichung von zwei oder mehr wirkstoffen
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
AU2011224397A1 (en) * 2010-03-09 2012-09-06 Stc.Unm Apparatuses and methods for microparticle dry coating of surfaces
WO2012030664A1 (en) * 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
WO2012044736A1 (en) 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
RU2697862C2 (ru) * 2012-02-28 2019-08-21 Айсьютика Холдингз Инк. Ингаляционные фармацевтические композиции
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
MX366744B (es) * 2012-03-23 2019-06-28 Copamex S A De C V Composición super-hidrofóbica, su preparación y papel que presenta super-hidrofobicidad.
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
EP3019153B1 (de) * 2013-07-11 2018-09-05 Chiesi Farmaceutici S.p.A. Trockenpulverformulierung mit einem anticholinergikum, einem corticosteroid und einem beta-adrenergikum zur verabreichung mittels inhalation
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
AU2016279798B2 (en) * 2015-06-15 2021-07-08 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
CA3109525A1 (en) * 2018-08-30 2020-03-05 Hydro-Quebec Coated lithium ion rechargeable battery active materials
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
US12269041B2 (en) 2019-09-19 2025-04-08 New Jersey Institute Of Technology Spherical composite powder
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
JP2024125434A (ja) * 2021-07-20 2024-09-19 興和株式会社 新規吸入剤
WO2023187393A1 (en) 2022-03-31 2023-10-05 Hovione Scientia Limited Inhalation composite and carrier based formulation combination
EP4539821A1 (de) 2022-06-21 2025-04-23 Hovione Scientia Limited Kristalline pharmazeutische zusammensetzung zur inhalation mit zucker- und lipidverbundpartikeln und verfahren zur herstellung
CA3260235A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Pharmaceutical composition for a dry powder inhaler of coated, crystalline dry powder intended for inhalation

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240092A (en) 1970-01-08 1971-07-21 Dynamic Tools Ltd A swivel connector
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
EP0257915B1 (de) * 1986-08-11 1993-03-10 Innovata Biomed Limited Mikrokapseln enthaltende pharmazeutische Zusammensetzungen
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
JP2668880B2 (ja) 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US5190764A (en) 1988-03-03 1993-03-02 Hokko Chemical Industry Co., Ltd. Agent for imparting a sustained release property to a pesticide, a pesticide having a sustained release property and a process for the production thereof
US5223244A (en) 1988-06-20 1993-06-29 Shiseido Company, Ltd. Aerosol composition
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0705614B1 (de) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Inhalationsvorrichtung für Trockenpulver
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IL98310A (en) 1990-06-08 1996-08-04 Astra Ab Pharmaceutical compositions comprising cystine derivatives
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5413804A (en) * 1991-04-23 1995-05-09 Cacique, Inc. Process for making whey-derived fat substitute product and products thereof
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
JP2735979B2 (ja) * 1992-04-23 1998-04-02 花王株式会社 樹脂粉末及び化粧料
AU659328B2 (en) * 1992-06-12 1995-05-11 Teijin Limited Ultrafine powder for inhalation and production thereof
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
JPH0696517A (ja) 1992-09-11 1994-04-08 Matsushita Electric Ind Co Ltd 磁気ディスク装置
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5441753A (en) * 1994-01-28 1995-08-15 Fmc Corporation Coprocessed particulate bulking and formulating AIDS: their composition, production, and use
EP1462096B1 (de) * 1994-03-07 2008-12-10 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US5711934A (en) * 1994-04-11 1998-01-27 Abbott Laboratories Process for the continuous milling of aerosol pharmaceutical formulations in aerosol propellants
US5647347A (en) 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
US6103271A (en) 1994-12-02 2000-08-15 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulation and electrostatic processing method
AR002009A1 (es) 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
FI972655L (fi) * 1994-12-22 1997-06-19 Astra Ab Aerosolilääkeformuloinnit
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
SE9502799D0 (sv) 1995-08-10 1995-08-10 Astra Ab Device in inhalers
US5738665A (en) 1996-09-26 1998-04-14 Becton, Dickinson And Company Shield and actuator for needles
US7366670B1 (en) 1997-08-05 2008-04-29 At&T Corp. Method and system for aligning natural and synthetic video to speech synthesis
US5997846A (en) 1997-11-17 1999-12-07 Albert Einstein College Of Medicine Of Yeshiva University Method for detecting arthropods
US6178414B1 (en) * 1997-12-16 2001-01-23 Nortel Networks Limited Method and apparatus for updating and searching an ordered list of values stored within a memory resource
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US20030118514A1 (en) * 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
CN1145478C (zh) 1998-04-18 2004-04-14 葛兰素集团有限公司 药用气溶胶制剂
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20010020242A1 (en) * 1998-11-16 2001-09-06 Amit Gupta Method and apparatus for processing client information
KR20010082309A (ko) * 1998-11-18 2001-08-29 로날드 엠. 쿠들라 코팅된 약물 입자 및 이것의 약제학적 제형의 제조방법
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
GB9826783D0 (en) 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6542490B1 (en) * 1999-01-29 2003-04-01 Nortel Networks Limited Data link control proctocol for 3G wireless system
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
DE69936268T2 (de) 1999-03-05 2008-02-14 Chiesi Farmaceutici S.P.A. Verbesserte pulverförmige pharmazeutische Zusammensetzungen zur Verwendung in Trockenpulverinhalatoren
US7090831B1 (en) 1999-04-14 2006-08-15 Smithkline Beecham Corporation Pharmaceutical aerosol formulation
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
US6197369B1 (en) * 1999-09-30 2001-03-06 New Jersey Institute Of Technology Method of particle coating
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
KR100949539B1 (ko) 2000-06-27 2010-03-25 벡투라 리미티드 약학 조성물용 입자의 제조 방법
US6404772B1 (en) * 2000-07-27 2002-06-11 Symbol Technologies, Inc. Voice and data wireless communications network and method
NZ525054A (en) 2000-10-09 2004-11-26 3M Innovative Properties Co Medicinal aerosol formulations
SK285389B6 (sk) 2000-10-12 2006-12-07 Boehringer Ingelheim Pharma Kg Inhalačný prášok s obsahom tiotrópia, kapsula s jeho obsahom a ich použitie
PT2283818T (pt) * 2000-11-30 2017-10-09 Vectura Ltd Método de preparação de partículas para utilização numa composição farmacêutica
PT1337239E (pt) 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
US20060147389A1 (en) 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
EP1663164A2 (de) 2003-09-15 2006-06-07 Vectura Limited Verfahren zur herstellung von pharmazeutischen zusammensetzungen
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
CN102655855B (zh) * 2009-12-14 2015-03-11 奇斯药制品公司 用于吸入的抗生素微粒

Also Published As

Publication number Publication date
CY1115304T1 (el) 2017-01-04
US9962338B2 (en) 2018-05-08
EP2298279A2 (de) 2011-03-23
EP2283817B1 (de) 2016-05-18
EP1920763B1 (de) 2014-04-02
CY1112338T1 (el) 2015-12-09
US9931304B2 (en) 2018-04-03
DK1920763T3 (da) 2014-07-07
EP1920763A1 (de) 2008-05-14
ATE382335T1 (de) 2008-01-15
US8956661B2 (en) 2015-02-17
EP2298285A3 (de) 2011-07-27
US20130017267A1 (en) 2013-01-17
PT2283817T (pt) 2016-08-22
DK2283817T3 (en) 2016-09-05
US10973771B2 (en) 2021-04-13
HK1154347A1 (en) 2012-04-20
PT1337240E (pt) 2011-11-02
EP2283818A1 (de) 2011-02-16
PT1920763E (pt) 2014-06-25
US8435567B2 (en) 2013-05-07
EP2298279A3 (de) 2011-08-03
US7736670B2 (en) 2010-06-15
US20130344156A1 (en) 2013-12-26
US8303991B2 (en) 2012-11-06
US20040037785A1 (en) 2004-02-26
EP1920763B2 (de) 2022-06-15
US20040047810A1 (en) 2004-03-11
ES2708961T3 (es) 2019-04-12
US10188612B2 (en) 2019-01-29
US20170266122A1 (en) 2017-09-21
EP2298285A2 (de) 2011-03-23
US20170172947A1 (en) 2017-06-22
ES2474199T3 (es) 2014-07-08
US20150086640A1 (en) 2015-03-26
EP2298279B1 (de) 2018-11-14
DK1337240T3 (da) 2011-11-21
US20100209358A1 (en) 2010-08-19
JP2009242408A (ja) 2009-10-22
EP2283817A1 (de) 2011-02-16
US20120027863A1 (en) 2012-02-02
EP2283818B1 (de) 2017-08-02
US20150079185A1 (en) 2015-03-19
US8048451B2 (en) 2011-11-01
US10449161B2 (en) 2019-10-22
PT2283818T (pt) 2017-10-09
US8932635B2 (en) 2015-01-13
EP3269360A1 (de) 2018-01-17
US20160243046A1 (en) 2016-08-25
JP5192447B2 (ja) 2013-05-08
DK1337240T4 (en) 2015-01-05
ES2587135T3 (es) 2016-10-20
HK1058145A1 (en) 2004-05-07

Similar Documents

Publication Publication Date Title
ATE517607T1 (de) Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung
ATE446085T1 (de) Partikel zur verwendung in einer pharmazeutischen zusammensetzung
CY1117749T1 (el) Μεθοδος παρασκευης σωματιδιων για χρηση σε φαρμακευτικη συνθεση
DE60137950D1 (de) Verfahren zur herstellung vitamin-k-abhängiger proteine
ATE270894T1 (de) Verfahren zur herstellung und verwendung von phytochemikalien
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
DE60105147D1 (de) Verfahren zur Herstellung einer stabilen mikronisierten Zusammensetzung von Formoterol mit einem Glucocorticosteroid
DE60221367D1 (de) ZUSAMMENSETZUNG ZUR PRÄVENTION VON OSTEOPOROSE bestehend aus EINER KOMBINATION AUS ISOFLAVONEN UND POLYUNGESÄTTIGTEN FETTSÄUREN
ATE276748T1 (de) Verfahren zur herstellung einer stabilen pharmazeutischen zusammensetzung enthaltend mikronisiertes formoterol
DE69526854D1 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
DE50000866D1 (de) Verfahren zur herstellung von festen cyclodextrinhaltigen dosierungsformen
ATE281125T1 (de) Verfahren zur herstellung von zahnersatz
ATE401313T1 (de) Herstellung von risperidon
ATE380016T1 (de) Aufstreuverfahren zur herstellung von pulverformulierungen
ATE294137T1 (de) Verfahren zur herstellung von orthokieselsäure, sowie nach dem verfahren hergestellte kieselsäure und ihre verwendung
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
DE602004025145D1 (de) Zusammengesetzte strukturen mit hyaluronsäure und derivaten davon als neue knochensubstitute und transplantate
DE60129518D1 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
DE60305438D1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE60309834D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung von lungenkrebs
ATE406810T1 (de) Zusammensetzungen enthaltend protein und fettsäure und verfahren zur herstellung
BR0017091A (pt) Uso de um composto, composição perfumante ou produto perfumado, composição aromatizante ou produto aromatizado, e, processo para conferir, aperfeiçoar, aumentar ou modificar as propriedades aromatizantes do tipo mandarina ou tangerina de uma composição aromatizante ou de um produto aromatizado

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1337240

Country of ref document: EP